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Abstract
Hypermethylation of the glutathione S-transferase p 1( GSTP1) gene promoter region has been reported to be a potential
biomarker to distinguish hepatocellular carcinoma (HCC) from other liver diseases. However, reports regarding how specific
a marker it is have ranged from 100% to 0%. We hypothesized that, to a large extent, the variation of specificity depends on
the location of the CpG sites analyzed. To test this hypothesis, we compared the methylation status of the GSTP1 promoter
region of the DNA isolated from HCC, cirrhosis, hepatitis, and normal liver tissues by bisulfite–PCR sequencing. We found
that the 59 region of the position 248 nt from the transcription start site of the GSTP1 gene is selectively methylated in HCC,
whereas the 39 region is methylated in all liver tissues examined, including normal liver and the HCC tissue. Interestingly,
when DNA derived from fetal liver and 11 nonhepatic normal tissue was also examined by bisulfite-PCR sequencing, we
found that methylation of the 39 region of the promoter appeared to be liver-specific. A methylation-specific PCR assay
targeting the 59 region of the promoter was developed and used to quantify the methylated GSTP1 gene in various diseased
liver tissues including HCC. When we used an assay targeting the 39 region, we found that the methylation of the 59-end of
the GSTP1 promoter was significantly more specific than that of the 39-end (97.1% vs. 60%, p,0.0001 by Fisher’s exact test)
for distinguishing HCC (n=120) from hepatitis (n=35) and cirrhosis (n=35). Encouragingly, 33.8% of the AFP-negative HCC
contained the methylated GSTP1 gene. This study clearly demonstrates the importance of the location of CpG site
methylation for HCC specificity and how liver-specific DNA methylation should be considered when an epigenetic DNA
marker is studied for detection of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the third or fourth leading
cause of cancer deaths in the world, the second fastest growing
cancer, and is now one of the top 10 causes of cancer deaths in the
United States [1]. It is usually an aggressive malignancy with a 5-
year survival rate of as low as 14% [1,2]. The 5-year survival rate
of patients with early-stage HCC is 26% but only 2% when it is
found after metastasis to distant organs. Therefore, early detection
is critical for effective treatment of HCC. The current circulating
marker, alpha-fetoprotein (AFP), and its fucosylated glycoform,
L3, are of limited value, with a sensitivity of only 40% to 60% [3].
Thus, there is an urgent need for a better marker or panel of
markers for the early detection of HCC.
The development of HCC, as with other solid tumors, is
believed to require the dysregulation of at least three biochemical
pathways (proliferation, cell cycle, apoptosis/cell survival) within
the cell [4,5,6]. In addition to genetic mutations, the aberrant
methylation of tumor suppressors plays an important role
throughout the process of HCC carcinogenesis. Due to the high
heterogeneity of HCC, a panel of markers may be needed to
provide sufficient sensitivity for its detection, and combinations of
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35789markers for HCC detection and management have been suggested
by several groups [7,8,9,10,11,12,13,14,15].
For biomarkers to be most useful for early detection or
screening, one would need to be able to detect the markers
without biopsy, such as in the circulation. In the course of
assembling a panel of HCC markers that have been detected in the
blood of patients with HCC for the development of a potential
screening test for the early detection of HCC, we noticed that
methylated glutathione S-transferase p 1( m GSTP1), one of the
extensively studied DNA markers, was detected in the circulation
of patients with HCC [16,17,18,19]. However, variability in the
HCC specificity of mGSTP1 has been reported in a number of
previously published studies, examples of which are shown in
Table 1.
The GSTP1 gene encodes glutathione S-transferase p, which
protects normal hepatocytes against a number of mutation-
inducing processes, such as reactive oxygen species linked with
chronic hepatic inflammation and reactive electrophilic com-
pounds linked with the hepatic metabolism of dietary and other
carcinogens [20,21,22,23]. Hypermethylation of its promoter
region has been shown to suppress the expression of the GSTP1
gene [24,25,26]. Thus, the hypermethylation of the promoter of
the GSTP1 gene has been associated with various cancers,
including HCC [9,10,11,13,14,24,27,28,29,30,31].
Recent evidence, as reviewed by van Vlodrop, has implicated
the impact of the location of aberrant CpG dinucleotide
methylation on gene expression and on its clinical value in cancer
[32]. This work suggests that the current data on hypermethyla-
tion markers require a more comprehensive and critical evaluation
prior to their implementation in clinical practice. Our recent study
of the methylation of the adenomatous polyposis coli (APC) gene
also suggested that not only the location of CpG methylation but
also the strand of DNA analyzed could have an impact on the
specificity of the methylated APC gene as a marker to distinguish
HCC from other liver diseases [33]. In this study, the APC gene
was found to be methylated preferentially on the antisense strand
of the DNA in normal liver. Thus methylation of the CpG sites
only on the sense strand of the APC gene is specific for HCC.
Interestingly, Millar et al. [34] studied the association of aberrant
methylation of the GSTP1 with prostate cancer and noticed that
DNA methylation of the sense strand of the GSTP1 gene in normal
liver appeared to be different from that from nine other organs
examined. We thus hypothesized that the variability of HCC
specificity of the mGSTP1 gene observed in previous studies could
be due to the region of the promoter analyzed.
Patients with hepatitis or cirrhosis are known to be at high risk
for HCC. Thus, a biomarker for HCC screening that distinguishes
HCC from hepatitis and cirrhosis would be of particular
usefulness. Although several studies have suggested a role for the
mGSTP1 promoter as a biomarker for HCC detection, to our
knowledge, the methylation status of the GSTP1 promoter has not
been analyzed by bisulfite sequencing, which is used to analyze
every CpG site in the region examined, across the spectrum of
normal liver, hepatitis, cirrhosis, and HCC. In this study, we
performed a comprehensive detailed methylation analysis using
bisulfite sequencing for both sense and antisense strands in normal
and diseased liver tissue (hepatitis, cirrhosis, and matched HCC
and adjacent non-HCC) in order to identify HCC-specific CpG
sites to develop an assay in the future study that would detect
mGSTP1 specifically in the circulation. We demonstrated that only
methylation of a subset of the CpG sites in the GSTP1 promoter,
the 59 end of the position 248 nucleotide [nt] relative to the
transcription start site, was methylated specifically in HCC and
also confirmed that the methylation of the CpG sites of the GSTP1
gene at the 39-end promoter region occurs in the normal liver and
appears to be liver specific compared to DNA isolated from 12
other normal tissues. Furthermore, after comparing the matched
adjacent non-HCC tissues, we suggest a cancer field effect of
GSTP1 methylation.
Results
DNA methylation profiles of the promoter region of the
GSTP1 gene in normal liver and diseased liver tissues
To test the hypothesis that the variable specificities of the
methylated GSTP1 (mGSTP1) gene for HCC reported in previous
studies could be due to the location within the gene analyzed, a
comprehensive survey of the promoter region using a bisulfite-
specific PCR (BS-PCR) assay followed by DNA sequencing was
performed. Because we previously demonstrated that methylation
could occur in a strand-biased manner, such as the antisense
strand-biased methylation of the APC gene in normal liver [33], it
was of interest to determine whether the methylation of the GSTP1
promoter in liver was also DNA strand-biased. Therefore, we
examined the methylation profile of both the sense and the
antisense strands of the GSTP1 promoter region. Bisulfite-specific
primers (BSP) for both the sense (GSTP1_BSP_S) and antisense
strands (GSTP1_BSP_AS) of the promoter region were designed to
include most of the CpG sites that were analyzed in the previous
studies listed in Table 1. Figure 1A shows CpG sites (vertical bars)
in the promoter and first exon regions of the GSTP1 gene, along
with locations of BSP primers (primer sequences are listed in Table
S1). All 32 CpG sites within the region studied were numbered
Table 1. Examples of the variable specificities of methylated GSTP1 genes for HCC reported in previous studies.
Study
GSTP1 Methylation # methylated/total
(%) CpG Sites Studied
1 Sensitivity (%) Specificity (%) Method Analyzed
HCC Normal liver
1 [14] 18/34 (53) 0/16 (0) 227 to 27 53 100 MethyLight
2 [7] 46/60 (77) 0/20 (0) 219 to 26 77 100 MSP
3 [13] 28/51 (54) 3/22 (13.7) 219 to 27 54 86.4 MSP
4 [42] 16/20 (80) 3/3 (100) 211 to +4 80 0 Pyrosequencing
5 [15] 24/40 (60) 12/25 (48) 24t o+7 60 48 MethyLight
1The CpG site number is referred to the transcription start site.
HCC, hepatocellular carcinoma; MSP, methylation-specific PCR.
doi:10.1371/journal.pone.0035789.t001
GSTP1 Methylation Pattern in HCC and Normal Liver
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35789Figure 1. Methylation profiles of the sense and antisense strands of the GSTP1 gene by BSP sequencing of DNA isolated from
normal liver and diseased liver tissues. (A) Diagram of the locations of bisulfite sequencing primers and the CpG sites, indicated by vertical bars,
in the promoter and the first exon regions of the GSTP1 gene (Genbank accession #M24485, nt. 999–1387). The transcription start site (TSS) is also
indicated. The CpG sites are bracketed by the bisulfite sequencing primers for the forward (F) and reverse (R) sense strands (GSTP1_S_F and
GSTP1_S_R) and the antisense strands (GSTP1_AS_F and GSTP1_AS_R). (B) Methylation status of each CpG site in both sense (S) and antisense (AS)
strands of the promoter and the first exon regions of the GSTP1 gene from 228 to +4 on the basis of the sense strand 59 to 39 direction relative to TSS
in hepatocellular carcinoma (HCC, n=20) tissue, matched adjacent non-HCC liver tissue (Adj Non-HCC, n=20), and normal (n=6), hepatitis (n=5),
and cirrhosis (n=5) tissues. The filled boxes indicate methylation detected and open boxes indicate no methylation detected. (C) Analysis of the
extent of methylation at each CpG site of the sense strand GSTP1 gene by BS-PCR sequencing of DNA isolated from normal liver and diseased liver
tissues. CpG site locations, BS-PCR sequencing assay, and DNA samples are the same as in panel B. The filled boxes indicate a high level of
methylation detected (more than 50%); hatched boxes indicate a low level of methylation detected (50% or less); and open boxes indicate no
methylation detected.
doi:10.1371/journal.pone.0035789.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35789from 228 to +4 relative to the transcription start site in the 59 to 39
direction.
To determine the assay sensitivity of each BS-PCR sequencing
reaction detecting the methylated CpG, we performed a
reconstitution experiment using a set of standards with varying
proportions of methylated DNA as indicated in Figure S1. We
found that, although the BS-PCR sequencing assays for both the
sense and antisense strands were able to consistently detect
methylated CpG in samples containing 10% methylated DNA
present in an excess of 90% unmethylated DNA, the resolution of
the extent of methylation was higher for the sense assay than for
the antisense assay. When a sample containing 10% methylated
DNA was tested in the reconstitution experiments, the sequencing
chromatograph generated by the antisense BS-PCR sequencing
assay showed only the ‘‘C’’ peak, whereas a mix of ‘‘C’’ and ‘‘T’’
peaks were observed with the sense BS-PCR sequencing assay.
With the sensitivity of the assay determined, we performed BS-
PCR sequencing in normal (n=6) and diseased liver including
hepatitis (n=5), cirrhosis (n=5), and HCC and matched non-
HCC tissues (n=20). The clinicopathological information for the
study subjects is described in Table 2. To control for the efficiency
of the bisulfite conversion, we determined the percentage of
cytosine-to-thymine conversions that occurred in non-CpG
cytosines within the analyzed region after DNA sequencing of
BSP product from each sample. Only samples yielding a cytosine-
to-thymine conversion rate higher than 95% for these non-CpG
Cs were analyzed further.
Due to the different resolutions obtained using the sense and
antisense BS-PCR sequencing assays, we constructed the methyl-
ation profile of the GSTP1 promoter for both sense and antisense
strands using a dichotomized variable: methylation detected or
undetected, as shown in Figure 1B. As suggested by Millar et al.
[34], when we studied the methylation status of the sense strand of
the GSTP1 promoter, we found that the CpG sites of the sense
strand of the GSTP1 DNA from 27t o+4 were methylated in
normal liver tissue and that the methylation was mostly
symmetrical for both sense and antisense strands of the DNA. In
contrast, most of the first 21 CpG sites (228 to 28) were not
methylated on either the sense or the antisense strand of DNA
(Fig. 1B), although minimal nonsymmetrical methylation was
observed in some samples. We thus divided the region examined
into the 59-end of the GSTP1 promoter, which included CpG sites
228 to 28, or those upstream from the nt position 248 from the
transcription start site, and the 39-end of the promoter, which
included CpG sites 27t o+4, or those downstream from the nt
position 248 in this study. Interestingly, the majority of the CpG
sites in the 59-end of the promoter region did not appear to be
methylated in either hepatitis or cirrhotic liver but were
methylated in HCC and even adjacent non-HCC liver tissues,
as shown in Figure 1B.
Because the variable specificities of the mGSTP1 gene for HCC
reported in previous studies were all obtained from an analysis of
the sense strand, to test our hypothesis, we compared the
specificities of the 39-end and 59-end of the GSTP1 gene only on
the sense strand and categorized the extent of methylation
obtained from results from the reconstitution experiments
(supplemental Figure 1) into three categories: no methylation
detected (0% detectable methylated DNA); low level of methyl-
ation detected (both ‘‘C’’ and ‘‘T’’ peaks detected, 0–50%
methylated DNA), and a high level of methylation detected (‘‘C’’
peak only, .50% methylated DNA) as shown in Figure 1C. We
calculated the percent of the methylated CpG sites detected per
total CpG sites analyzed for both the 39-end and 59-end regions, as
shown in Table 3. For the region of the 59-end promoter, low
levels of methylation were detected in normal (11.1%), hepatitis
(8.6%), cirrhosis (13.3%), adjacent non-HCC (36.9%), and HCC
(59.8%) tissue; however, only the CpG sites in the HCC tissue
contained a high level of methylation (5.2%). The mean level of
methylation detected (low+high), together with the corresponding
standard deviation, was calculated for each tissue group. To see if
the specificity of mGSTP1 for HCC differed between the 39-end
and the 59-end, we determined the p value of HCC compared with
those of all liver tissues from non-HCC patients (cirrhosis+hepa-
titis+normal liver) for each region. As indicated by Fig. 1B, an
increase in the amount of methylation was observed in adjacent
non-HCC tissue compared to that of normal liver. Of interest, we
also determined the p value of the HCC tissue compared with all
non-HCC tissues including adjacent non-HCC tissue, cirrhosis,
hepatitis, and normal liver. As shown in Table 3, the level of
methylation was significantly higher (p,0.0001: by Student’s t test)
in the HCC compared to the non-HCC groups (both with and
without the adjacent non-HCC tissue). In contrast, a similar
analysis was performed for the region of the 39-end promoter; no
significant difference was obtained (p.0.05) for the amount of
methylation detected in the HCC group compared with the non-
HCC groups (with or without adjacent non-HCC). These data
suggested that the methylation of the 59-end promoter, compared
to the 39-end, should have more discriminatory power (specificity)
to distinguish HCC from hepatitis and cirrhosis.
Table 2. Summary of clinicopathological characteristics of the tissues analyzed by BSP sequencing.
Characteristic Normal
1 (n=6) Hepatitis (n=5) Cirrhosis (n=5) HCC (n=20)
Mean age ± SD, years 6467.5 59.8610.3 60.6614.9 60.2612.4
Male/female 4/2 4/1 2/3 11/9
HBV/HCV/other 0/0/0 2/3/1 2/2/1 7/9/5
Stage 1/2/3/4/unknown ---1 0 / 7 / 1 /1/1
Grade 1/2/3/unknown - - - 3/11/5/1
Mean size of tumor ± SD, cm - - - 5.2762.67
AFP levels, ng/mL, #20/.20/unknown - - - 8/11/1
14/6 of the 6 normal livers are ‘‘normal’’ liver tissues with concomitant cholangiocarcinoma.
AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SD, standard deviation.
doi:10.1371/journal.pone.0035789.t002
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35789Methylation profile of the promoter region of the GSTP1
gene in non-liver normal tissues
Our recent study showed the presence of liver-specific,
antisense-biased CpG methylation in the promoter region of the
tumor suppressor APC gene [33]. Millar et al. [34] suggested that,
on analysis of the sense strand of the DNA from eight different
tissue samples, methylation of the 39-end of the promoter region of
the GSTP1 gene was found only in normal liver [34]. Thus, to
determine if the methylation pattern of the GSTP1 promoter seen
in normal liver tissue is liver-specific, we examined the methylation
profile of both the sense and the antisense strands of the GSTP1
promoter region in 11 other non-liver normal tissues including
pancreas, peripheral blood monocytes, lung, heart, colon,
esophagus, kidney, spleen, stomach, breast, and trigeminal
ganglion and 1 fetal liver, as shown in Figure 2. As a reference
of normal adult liver, we included the methylation profiles from
two normal livers from normal healthy subjects in Figure 2. All 11
nonliver and 1 fetal liver normal tissue samples showed no
detectable methylation in either the 59-end or the 39-end of the
promoter regions, indicating that methylation of the 39-end
promoter region of the GSTP1 appears to be liver-specific.
Evaluation of the specificity of the mGSTP1 promoter in
distinguishing HCC from other liver diseases by the
methylation-specific PCR assay (MSP)
Bisulfite sequencing is a method used to analyze the methylation
status of every CpG site in the region of interest, but it is labor
intensive to analyze a large panel of samples representing the
different stages of disease progression to HCC. To confirm our
results from the BS-PCR sequencing, showing that the methyla-
tion of the 59-end region of the GSTP1 promoter is more specific to
HCC than that of the 39-end region in a large sample of tissues, we
developed an MSP assay targeting the CpG sites that showed
higher HCC specificity when analyzed by BS-PCR sequencing
(Fig. 1B) in the 59-end promoter region. In this MSP assay, the
CpG sites included in the forward primer, the TaqMan probe, and
the reverse primers are 227 to 224, 223 to 219, and 211 and
210, respectively (Fig. 3A). The sequences of the primers and
probe and the PCR conditions are described in Table S1. Using
this assay, we were able to quantify methylated DNA with an assay
sensitivity of 10 copies per reaction, as shown in Figure S2A. As a
comparison, we used an MSP assay reported previously [15] to
target the 39-end of the GSTP1 promoter region. This assay has a
sensitivity and linear range for quantifying the mGSTP1 gene
comparable to the 59-end MSP assay that we developed, as shown
in Figure S2B.
Next, we compared the performance of mGSTP1 in the 59-end
MSP assay with that in the 39-end MSP assay [15] in
distinguishing HCC from hepatitis and cirrhosis. The DNA
isolated from hepatitis (n=35), cirrhosis (n=35), adjacent non-
HCC (n=120), and HCC samples (n=120) was treated with
bisulfite and quantified by the BS-actin PCR assay as described
previously [33]. The clinicopathological characteristics of the
study subjects are shown in Table 4, which includes the study
subjects used in the BS-PCR sequencing assays. The amount of
methylated GSTP1 promoter was determined for each segment of
BS-converted DNA by MSP assays in duplicate, and the receiver
operating characteristic (ROC) curves were constructed accord-
ingly to evaluate the performance of the mGSTP1 promoter as a
biomarker to distinguish HCC from non-HCC including hepatitis
and cirrhosis (Fig. 3B). We also constructed and compared ROC
curves for HCC tissue and for non-HCC tissues including adjacent
non-HCC tissues (Fig. 3C). The specificity and sensitivity were
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35789calculated on the basis of the cutoff value of 10 copies since that is
the limit of the quantification for both 39-end and 59-end MSP
assays. As listed in the table inset in Figure 3B, as a biomarker to
distinguish HCC from non-HCC liver diseases, the methylation of
the 59-end of the GSTP1 promoter was significantly more specific
than that of the 39-end (97.1% vs. 60%, p,0.0001 by Fisher’s
exact test), although the 59-end was less sensitive than the 39-end
(37.5% vs. 80%), and the AUROC curves for both regions were
similar (0.760 and 0.775). We obtained a similar result, i.e.,
significantly more specific methylation at the 59-end of the GSTP1
promoter than at the 39-end (96.8% vs. 55.8%, p,0.0001 by
Fisher’s exact test), when the comparison included the adjacent
non-HCC tissues (Fig. 3C).
Identification of the AFP-negative HCC by mGSTP1
As discussed earlier, the current ‘‘gold standard’’ serum marker,
AFP and its fucosylated glycoform, L3, is of limited value because
they have sensitivities of only 40% to 60% [3]. Moreover, there is
currently no biochemical marker that can detect AFP-negative
HCC, in which the serum AFP level is less than 20 ng/mL, as
suggested by the American Association of Liver Diseases [3].
Because mGSTP1 was previously detected in the blood of patients
with HCC [16,17,18,19], it was of interest to see whether we could
detect GSTP1 methylation in the HCC samples that were negative
for AFP. We thus analyzed the incidence of mGSTP1 in the HCC
tissues for which AFP values were available (n=115). We plotted
the quantity of serum AFP on the x-axis and mGSTP1 in tissue on
the y-axis for each subject with HCC (Fig. 4). In this study
population, 62 patients (53.9%, 62/115) with HCC had AFP
serum levels less than 20 ng/mL and their HCC samples were
therefore considered to be AFP-negative. Encouragingly, mGSTP1
was found in 33.8% (21/62) of the AFP-negative HCC tissues,
thus increasing the sensitivity of detecting HCC in tissues for
which AFP values were available to us (n=115) from 46.1% (53/
115) with AFP alone to 64.3% (74/115) by combining two
markers.
Discussion
In this study, we observed that only the 59 region of the 32 CpG
sites examined (numbered 228 to +4 relative to the transcription
start site) in the promoter region of the GSTP1 gene that are
methylated specifically in HCC compared to normal liver and
hepatitis and cirrhotic liver tissues. On the other hand, CpG
methylation was observed in the 39 region (CpG sites from the 27
to +4) in most of the liver tissues studied including normal liver.
We demonstrated that the MSP assay, designed for the 39 region
to analyze the mGSTP1 promoter for distinguishing HCC from
cirrhosis and hepatitis, would have poor specificity (60%). In
contrast, a high specificity (97.1%) was obtained when the MSP
assay was designed for the 59 region of the promoter (Figure 3).
These data not only prove our hypothesis that the location of the
GSTP1 DNA analyzed for methylation impacts the specificity for
HCC as a biomarker for HCC detection but also provides an
interpretation for the variation in HCC specificity of the mGSTP1
promoter to distinguish HCC from other liver-disease tissues
reported in previous publications, as examples listed in Table 1. As
discussed, a recent review by von Vlodrop suggested the
importance of the locations of CpG methylation in relation to
gene expression and of the associations with clinicopathological
characteristics in cancer [32]. For instance, only one of the three
Figure 2. Methylation status of the sense (S) and antisense (AS) strands of the promoter and the first exon region of the GSTP1 gene
(Genebank accession #M24485, nt. 999–1387) of the DNA isolated from normal adult livers, fetal liver, and normal nonliver
tissues. The open boxes indicate unmethylated CpG sites; the filled boxes indicate methylation detected.
doi:10.1371/journal.pone.0035789.g002
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with poor survival in clear cell renal carcinoma [35]. Together
with the results of our recent studies, which showed that strand-
biased methylation of the APC gene is present in liver and that
methylation of only the sense strand is specific for HCC [33], these
results highlight the importance of the locations of CpG
methylation of a given marker for clinical applications, particularly
in liver cancer, since both of the methylation markers we studied
exhibited a liver-specific DNA methylation pattern when com-
pared to the other 11 normal tissues examined.
We found significantly more detectable methylated CpG sites in
adjacent non-HCC tissue compared to normal, hepatitis, and
cirrhotic liver tissue using BS-PCR sequencing in the 59 end region
(p,0.0001 by Fisher’s exact test), suggesting that methylation of
Figure 3. Comparison of the specificity of the 59-end and the 3-end of the mGSTP1 as a biomarker to distinguish HCC samples from
tissue samples of other liver diseases, as determined by MSP assays. (A) Locations of forward (F) and reverse (R) primers and TaqMan probe
(P) of the 59-end MSP (59-MSP) (including the TaqMan probe) and 39-end MSP (39-MSP) SybrGreen assays. The CpG sites (vertical bars) and the
transcription start site (TSS) are indicated. Receiver operating characteristic (ROC) curves of the methylated GSTP1 gene as a marker to discriminate
HCC (n=120) from non-HCC liver tissues including hepatitis (n=35) and cirrhosis (n=35) (B), or hepatitis, cirrhosis, and adjacent non-HCC (C),
generated by 59-end MSP and 39-end MSP assays, respectively, as indicated. The amount of methylated DNA was the average of two duplicate MSP
assays as detailed in Materials and Methods. The area under the curve of each ROC (AUROC) curve and the specificity and sensitivity determined by
the cutoff of 10 copies per input of 300 copies of DNA are shown in the inserted table. Note that the CpG sites included in each primer and probe are
as follows; 59-end MSP (F: 227 to 224; P: 223 to 219; R: 211 to 210) and 39-end MSP (F: 24t o22; R: +4t o+7).
doi:10.1371/journal.pone.0035789.g003
Table 4. Summary of clinicopathological characteristics of the tissues analyzed using the MSP assays.
Characteristic Normal
1 (n=6) Hepatitis (n=35) Cirrhosis (n=35) HCC (n=120) P value
Mean age ± SD, years 6467.5 55611.62 56613.8 60611.3 0.07
2
Male/female 4/2 17/18 23/12 81/39 0.175
2
HBV/HCV/others 0/0/0 11/27/5 4/21/9 63/33/26 -
Stage 1/2/3/4/unknown - - - 48/48/16/4/4 -
Grade 1/2/3/unknown - - - 18/74/23/5 -
Mean size of tumor ± SD, cm - - - 5.3163.69 -
AFP levels, ng/mL, #20/.20/unknown - - - 62/53/5 -
14 of the 6 normal livers are ‘‘normal’’ liver tissues with concomitant cholangiocarcinoma.
2Across all subjects (n=196), age was analyzed by the Student t test and gender by Fisher’s exact test.
AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SD, standard deviation.
doi:10.1371/journal.pone.0035789.t004
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that results in HCC and that it plays a role in the cancer
microenvironment or field effect. To date, such field effect
biomarkers have been reported in several sites and organs, for
example, head and neck, colon and rectum, prostate, breast, lung,
esophagus, stomach, and skin, as reviewed by Chai 2009 [36], and
also HCC [37,38]. It has been suggested that the cancer
microenvironment or the cancer field effect plays an important
role in carcinogenesis [39] and that alterations in DNA
methylation patterns may contribute to the field effect [40,41].
Glutathione S-transferases are a family of enzymes that play an
important role in detoxification and are responsible for protecting
cells from cytotoxic and carcinogenic agents. Thus, one could
easily understand that, if this detoxification enzyme is insufficiently
expressed, the accumulation of carcinogens would promote
carcinogenesis and give rise to a tumor in the field. It has been
suggested that DNA methylation of the GSTP1 gene suppresses the
expression of GSTP1 mRNA and protein [24,25,26]. Our data
suggest that HCC-related DNA methylation does occur, although
to a lesser extent in the adjacent non-HCC tissues, suggesting that
methylation of the 59 region of the GSTP1 promoter could be part
of the cancer microenvironment that cultivates the development of
HCC. Because the methylation of the 39 region of the promoter
exists in the normal liver, it is possible that methylation of the 59
region has a more profound effect on suppression of the GSTP1
gene than originally thought. More study is needed to further
understand the role of methylation of the 39 region and 59 region
in the expression of the GSTP1 gene.
As mentioned above, it has been suggested that promoter
methylation of the GSTP1 gene is a potential marker for HCC
screening because this marker has been detected in the circulation
of patients with HCC [16,17,18,19] and could be a potential
marker in combination with other markers for diagnosis and
surveillance of persons at high risk for HCC. The methylation of
the 59 region was more specific (97.1% vs. 60%), but the sensitivity
of detecting HCC was significantly higher if methylation of the 39
region was analyzed (80% vs. 37.5%). As a result, the AUROC
curves for both regions were similar (0.760 and 0.775). This
finding suggests that HCC-related methylation occurs in the entire
region of the promoter. Thus, when the extent of methylation was
measured quantitatively, the increase in methylation was detected
in either region regardless of the basal level of methylation.
However, our study suggests that the assay to detect this marker
should target the 59 region of the promoter to obtain higher
specificity, particularly when the end-point MSP is used.
Although this marker was found in only 37.5% of the HCC
samples, the mGSTP1 marker was detected in 33.8% of AFP-
negative HCC in our study population. This result is important
because no biochemical marker is currently available to detect
AFP-negative HCC. Aberrant DNA methylation has already been
suggested for use in a screening test to identify subjects that are at
high risk for HCC. If one combines mGSTP1 and serum AFP and
detects the HCC specific region with the MSP assay, the sensitivity
can be improved from 46.1% to 64.3%. Thus, mGSTP1 could be a
potential marker for HCC screening that would be complemen-
tary to AFP levels.
Using BS-PCR sequencing, we were able to detect different
amounts of methylation at the 59 region of the promoter in all 20
of the HCC samples and in 17/20 of adjacent non-HCC samples
but limited amounts in hepatitis and cirrhosis tissue. Using the
MSP assay, we targeted the 59 region of the sense strand;
methylation of the GSTP1 gene was highly specific (97.1%
specificity) even when compared to the adjacent non-HCC tissue.
The BS-PCR sequencing data represent a collection of the
methylation at that particular site from the templates that were
amplified by a PCR reaction. This collection of methylation data
Figure 4. Scatter plot distribution of serum AFP levels (x-axis) and the amount of methylated 59-end of the GSTP1 DNA (mGTSP1) (y-
axis) for 115 HCC samples. Each circle represents the value for an individual HCC case. A vertical reference line intersects at an AFP value of 20 ng/
ml. A horizontal reference line intersects right above the MSP value of 0 as the reference for undetectable (ND), which is less than 10 copies per assay.
The number of HCC cases and the percent of the total HCC in each of four areas are indicated.
doi:10.1371/journal.pone.0035789.g004
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isolated from a given tissue. For a sample to be methylation
positive using an MSP assay, all of the CpG sites included in the
primers and probe would have to be methylated on one molecule
except for limited miss-priming. Thus, in adjacent non-HCC
samples, when we used BS-PCR sequencing and defined positive
as detectable methylated CpG sites (low+high, Fig. 1C), 36.9% of
CpG sites in the adjacent non-HCC samples were positive for 59-
end mGSTP1 (Table 3); in contrast, with the MSP assay, only 4 of
120 (3.3%) were positive for the 59-end. For HCC, with the BS-
PCR sequencing assay, 65% of CpG sites in the HCC samples
were positive for 59-end mGSTP1 (Table 3); only 45 of 120 (37.5%)
were positive when measured by the 59-end MSP assay.
Nevertheless, the data from both assays suggest a higher density
of methylation in the HCC samples compared to adjacent non-
HCC samples.
In this study, we used different detection technologies for two
MSP assays: TaqMan for the 59-end MSP and SYBR Green for
the 39-end MSP. It is possible the difference of the sensitivity and
specificity obtain by the these two methods is due to different
detection technologies because that the 59-end MSP could detect
only the DNA molecules that contained methylated CpG sites in
both primers and TaqMan probe locus, but the 39-end MSP only
tested CpG sites in the primers thus it is a less conservative assay.
However, this concern should not affect the conclusion of this
study that methylation of 59-end region is more specific than that
of the 39-end region for detecting HCC from other liver disease
tissues because this conclusion is also suggested by BS-CR
sequencing analysis (Fig. 1). Furthermore, the low (48%) - to
none (0%) specificity of the 39-end methylation were observed by
previous studies as we have referenced in Table 1 (study #4 [42]
and study #5 [15]) in which the TaqMan was used in [15] and
pyrosequencing was used in [42].
Interestingly, although most of the methylation detected in the
GSTP1 promoter region analyzed is symmetrical, some nonsym-
metrical methylation was detected by BS-PCR sequencing
(Fig. 1B). As discussed earlier, the BS-PCR sequencing data
represent methylated molecules collected from the templates at the
particular site and therefore do not represent individual molecule
in the pool of DNA isolated from a given tissue. Analysis by the
BS-PCR cloning sequencing will be needed to determine whether
the nonsymmetrical methylation observed is multiple, continuous
nonsymmetrical CpG site methylation on a molecule, as we
discovered in the APC gene [33], or a collection from many
templates, each of which contains 1 to 2 sparsely distributed
nonsymmetrical methylated CpG sites that occurred because of
errors of methylation. Nevertheless, most of the methylation in the
GSTP1 gene analyzed is symmetrical.
When we analyzed the different clinicopathologies (Table 5), we
did not find a significantly higher incidence of mGSTP1 in any of
the HCC subsets (p.0.5 by the Kruskal-Wallis test). It has been
suggested that infection with hepatitis B virus (HBV) or hepatitis C
virus (HCV) increases the aberrant methylation of tumor
suppressor genes in HCC, including the GSTP1 gene
[8,9,10,13,15,43], in HBV-infected HCC but not in non-HBV-
infected HCC or in non-HCV-infected HCC. This discrepancy
could be due to the differences in the clinicopathological
characteristics of the HCC tumors used in the different studies.
Cancer is a disease of the genome and epigenome; thus,
detection of genetic and epigenetic changes underlying the
development of HCC should aid in the unambiguous detection
of tumors. Interestingly, two of the potential HCC epigenetic
DNA markers we examined, methylation of the APC [33] and
GSTP1 genes, exhibit liver-specific methylation patterns, suggest-
ing that, in the search for epigenetic DNA markers for detection of
HCC, the methylation status of normal liver should be taken into
consideration when developing a sensitive and specific assay for
the detection of HCC.
Materials and Methods
Subjects
The HCC tissues and the matched adjacent non-HCC liver
samples used in this study were obtained with written informed
consent from patients who underwent radical resection at The
National Cheng-Kung University Medical center in accordance
with the guidelines of the National Cheng-Kung University
institutional review board. Archived DNA samples (35 hepatitis
and 35 cirrhosis) were obtained from the Buddhist Tzu Chi
Medical Center, Hualien, Taiwan, in accordance with the
Buddhist Tzu Chi Medical Center institutional review board
protocols. DNA from normal liver (n=4), esophageal, and colon
tissues was obtained from The Johns Hopkins University School of
Medicine in accordance with The Johns Hopkins University
Institutional Review Board protocols. The Institutional Review
Boards of Drexel University College of Medicine, the Buddhist
Tzu Chi Medical Center, The Johns Hopkins University School of
Medicine, and The National Cheng-Kung University Medical
center specifically approved this study. Normal liver (n=1), heart,
and lung tissue samples obtained from the National Disease
Research Interchange, Philadelphia were given to us by
Immunotope, Inc (Doylestown, PA), and normal peripheral blood
mononuclear cell DNA was obtained as a gift from the laboratory
of Dr. Pooja Jain (Drexel University College of Medicine). One
normal liver tissue DNA sample was purchased from Capital
Biosciences (Rockville, MD), and stomach 1–4, pancreas, kidney,
spleen, breast, brain, trigeminal ganglion, and fetal liver DNA was
purchased from Biochain (Hayward, CA). The subject profile is
listed in Table 2, Table 4 and Table S2.
DNA isolation and bisulfite treatment
DNA was isolated using the Qiagen DNAeasy Blood and Tissue
kit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions. The DNA concentration was measured using a
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific Inc,
Wilmington, DE) at 260 nm absorbance. Bisulfite treatment was
performed using Qiagen EpiTect Bisulfite conversion kits (Qiagen)
following the guidelines of the manufacturer.
Table 5. Aberrant methylation of the GSTP1 in HCC stratified
by clinicopathological characteristics.
Comparison of HCC samples (n=120) P value
1
Stage 0.723
Grade 0.160
HBV –HCC (n=63) vs. non-HBV-HCC (n=57) 0.801
HCV-HCC (n=33) vs. non-HCV-HCC (n=87) 0.906
AFP levels (,20 ng/mL vs. $20 ng/mL) 0.056
1Kruskal-Wallis test.
AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma;
HCV, hepatitis C virus.
doi:10.1371/journal.pone.0035789.t005
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and unmethylated DNA for BS-PCR sequencing and MSP
assays
To determine the assay sensitivity of BS-PCR sequencing and
MSP assays to detect methylated DNA and estimate the relative
amount of methylated DNA in a given sample, we prepared a
reconstituted sample set (i.e., a known amount of methylated DNA
in a background of unmethylated DNA). Bisulfite-converted
human universal methylated DNA control (Zymo Research,
Seattle, WA) was used as the methylated DNA standard.
Bisulfite-treated DNA from normal human peripheral blood
mononuclear cells that was confirmed by sequencing to be
unmethylated in the GSTP1 region of interest was used as a source
of unmethylated DNA and was quantified by the BS-actin real-
time PCR assay, which primers were designed within regions
lacking CpG sites, so that CpG methylation status would not affect
primer binding [33]. On the basis of quantification by BS-actin
PCR, reconstituted sample sets were prepared in the following
ratios: (1) 0% methylated DNA, 100% unmethylated DNA; (2)
10% methylated DNA, 90% unmethylated DNA; (3) 25%
methylated DNA, 75% unmethylated DNA; (4) 50% methylated
DNA, 50% unmethylated DNA; and (5) 100% methylated DNA.
BS-PCR DNA Sequencing
Bisulfite specific primers were designed using Methyl Primer
Express software (Life Technologies, Applied Biosystems, Foster
City,CA)toamplify thepromoterregionofthe GSTP1 gene forboth
the sense and antisense strands; the primer sequences are described
in Table S1. PCR was performed in an Eppendorf Mastercycler
thermocycler for 40 cycles with hot-start Taq polymerase (Qiagen).
The PCR program started with activation of the polymeraseat 95uC
for 15 min followed by denaturation at 95uC for 30 s, annealing at
the respective annealing temperature (Table S1) for 30 s, and
extension at 72uC for 30 s, followed by a final 4-min extension at
72uC and cooling at 4uC for all primer sets. The reaction was
assembled in a final volume of 20 ml containing 0.5 U HotStart Taq
(Qiagen), 16 PCR buffer, 200 mM of dNTPs, 0.5 mM of each
primer, and bisulfite-treated DNA templates. PCR products were
runon1%agarosegelwith16TAEbuffer.ThePCR product ofthe
correct size was excised, and the gel was purified with Qiagen Gel
Purification kit (Qiagen) and sent with the appropriate primer for
sequencing to the NAPcore facility at the Children’s Hospital of
Philadelphia, Philadelphia, PA. Sequencing results were analyzed
using ClustalW software (available at http://www.ch.embnet.org/),
Chromas 2.3 software (Technelysium, Tewantin, Queensland,
Australia), and Finch TV version 1.4.0 (Geospiza Inc, Seattle, WA).
MSP assays
A quantitative real-time methylation specific PCR (MSP) assay
for the 59-end region was developed with the primer pair and
Taqman probe as shown in Table S1, and illustrated in Figure 3.
More specifically, this is a MethyLight assay since a TaqMan
probe was included in addition to methylation specific primers
used in the assay. This 59-end MethyLight assay was referred as 59-
end methylation specific PCR (MSP) assay. For the 59-end MSP, A
10-ml reaction was assembled using the Roche Light Cycler 480
Real-Time PCR system (Roche Applied Science, Mannheim,
Germany). The reaction contained a 16LightCycler 480 Probes
Master, 1.0 mM primers, 0.2 mM probe, and the DNA template.
The PCR reaction was performed under the following conditions:
95uC 10 min, (95uC1 0s ,6 5 uC3 0s ,7 2 uC1 0s ) 650 cycles, 40uC
30 s. The MSP assay for the 39-end region used in the study was
modified from the method previously described [15] by using the
LightCycler 480 SYBR Green I Master. For the 39-end MSP, A
10-ml reaction was assembled using the LightCycler 480 SYBR
Green I Master (Roche Applied Science, Mannheim, Germany).
The reaction contained 16 LightCycler 480 SYBR Green I
Master, 1.0 mM primers, and the DNA template. The PCR
reaction was performed under the following conditions: 95uC
10 min, (95uC1 0s ,6 0 uC1 5s ,7 2 uC1 0s ) 645 cycles, melt curve
analysis (95uC 5 s, 65uC6 0s ,9 7 uC), 40uC3 0s .
Statistical Analysis
To test whether age and gender were evenly distributed across
both HCC and non-HCC groups, the Student t test was
performed for age and Fisher’s exact test was performed for
gender. To study the distribution of GSTP1 59-end MSP values in
HCC tissues across the categories of stage, grade, HBV status,
HCV status, and AFP groups (,20 or .20 ng/ml), a Kruskal-
Wallis test was performed. Stages 2, 3, and 4 were combined into
one group, and Grades 2 and 3 were combined into one group
because the numbers of samples in stage 3 (n=3), stage 4 (n=1),
and grade 3 (n=9) were low. ROC curves, areas under the ROC
curves, comparisons between ROCs and the scatter plot
distribution of serum AFP levels (y-axis) versus the amount of
mGSTP1 DNA distribution was constructed using the PASW
software (IBM, New York).
Supporting Information
Figure S1 The representative chromatograms of BSP
sequencing of the reconstituted standards: 0% methyl-
ated+100% unmethylated DNA (0%);10% methylated
DNA+90% unmethylated DNA (10%); 25% methylated
DNA+75% unmethylated DNA (25%); 50% methylated
DNA+50% unmethylated DNA (50%); and 100% methyl-
ated DNA (100%), from both sense (GSTP1_S_F/R) and
antisense (GSTP1_AS_F/R) bisulfite specific PCR se-
quencing primers, as indicated. The boxed areas are the
areas of the examples showing the relative ‘‘C’’ and ‘‘T’’ peaks in
the chromatogram from each sample of the reconstituted
standards by each primer set as indicated.
(TIF)
Figure S2 Amplification and standard curves of the 59-
end (A) and 39-end (B) MSP assays. Various concentrations
of human methylated bisulfite-converted genomic DNA reconsti-
tuted in unmethylated DNA controls, as indicated, were amplified
by the GSTP1 MSP assays as detailed in Materials and Methods.
The curves generated by different amounts of input DNA (copies)
per reaction are indicated.
(TIF)
Table S1
(DOCX)
Table S2
(DOCX)
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